Aug 17, 2026 · 8 min
AI chip rally collides with biotech failure and bond-market stress
Closing Bell: Chip Stocks Rise, SpaceX Gains, EyePoint Sinks
The market close shows how enthusiasm for AI-linked growth can coexist with sharp losses in drug development and rising pressure on bonds.
- 1Anthropic’s reported revenue growth helped lift AI-linked chip stocks, including SanDisk.
- 2EyePoint Pharmaceuticals plunged after its eye-disease treatment failed a late-stage trial.
- 3A bond-market sell-off pushed Treasury yields to multi-year highs as stocks moved sharply in both directions.
Don't miss
EyePoint Pharmaceuticals suffered a record drop after its eye-disease treatment failed a late-stage trial.
The brief
Carol Massar frames a market close shaped by sharply different forces: AI-linked chip stocks rallied on Anthropic’s revenue growth, while other sectors absorbed heavy losses.
SanDisk stood out among the day’s gainers as investors connected chip-stock strength to financial news surrounding Anthropic and the expanding AI economy.
Joe Deaux turns to the decliners, led by EyePoint Pharmaceuticals after its eye-disease treatment failed a late-stage trial and triggered a record drop.
The broader warning came from bonds: a sell-off pushed Treasury yields to multi-year highs, adding a second source of pressure beyond individual stocks.
The episode’s central contrast is a market rewarding AI-linked growth while punishing clinical failure and demanding higher returns from government debt.
What was said on this episode
8 statements · 4 positive · 3 negative · 1 mixed
SanDisk’s upbeat outlook contributed to a broader memory and storage stock rally.
“investors, you know, just pushing what has been a common narrative, this broader rally when it comes to memory and storage stocks after sandisk outlined an upbeat multi year financial outlook.”
Listen at 1:51
SanDisk is among the S&P 500’s top-performing stocks this year.
“SanDisk continuing to be really a high flyer this year. It is a top performing name by a wide margin in the S&P 500.”
Listen at 2:05
Investment firms for wealthy individuals have accumulated billions in SpaceX exposure.
“Investment firms for ultra wealthy individual individuals have built up billions of dollars of exposure to SpaceX.”
Listen at 2:23
More than a dozen family offices held at least $3.8 billion of SpaceX through mid-2026.
“more than a dozen family offices holding a total of at least 3.8 billion SpaceX through the first half of 2026”
Listen at 2:29
EyePoint’s experimental eye-disease treatment failed its late-stage primary endpoint.
“the drug developer said its experimental treatment for an eye disease failed to meet a primary goal in its late stage trial.”
Listen at 3:15
EyePoint’s failed trial does not necessarily end its prospects.
“that doesn't necessarily mean this is the end.”
Listen at 3:46
The 30-year Treasury yield reached its highest level since 2007.
“the 30 year yield now at the highest since 2007.”
Listen at 5:26
Risks in the bond market are increasingly tilted toward inflation.
“the balance of risk seems increasingly tilted towards inflation.”
Listen at 5:44
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.